24 studies found for:    Annexin V
Show Display Options
Rank Status Study
1 Withdrawn Effect of Ischemic Postconditioning on Targeting of Annexin A5 After Forearm Exercise
Conditions: Cardiovascular Disease;   Ischemia-Reperfusion Injury;   Postconditioning
Intervention: Procedure: repetitive short ischemia and reperfusion of non dominant fore arm after 10 minute ischemic exercise
2 Recruiting Effect of HCQ on AnxA5 Resistance Assay in Antiphospholipid (aPL) Positive Patients With and Without Systemic Lupus Erythematosus (SLE)
Conditions: Antiphospholipid Syndrome;   Thrombophilia Due to Antiphospholipid Antibody;   Systemic Lupus Erythematosus
Intervention: Other: Phlebotomy
3 Completed The Effect of Rosiglitazone on Ischemia-reperfusion-injury Using Annexin A5 Scintigraphy.
Conditions: Ischemia-Reperfusion Injury;   The Metabolic Syndrome
Intervention: Drug: rosiglitazone
4 Completed Ischemic Injury and Ischemic Preconditioning in Diabetes
Conditions: Diabetes Mellitus, Insulin-Dependent;   Ischemia-Reperfusion Injury
Interventions: Procedure: Ischemic preconditioning;   Procedure: Forearm ischemic exercise;   Procedure: Annexin A5 scintigraphy;   Drug: Diazoxide;   Drug: glibenclamide;   Drug: adenosine
5 Unknown  The Influence of the 34C>T Variant in the AMPD1 Gene Ischemic Tolerance
Conditions: AMPD;   Ischemic Tolerance
Interventions: Drug: systemic administration of 99mTc-HYNIC-Annexin A5;   Behavioral: 10 minutes of ischemic handgripping
6 Completed Rosuvastatin and Ischemia Reperfusion
Condition: Ischemia
Intervention: Drug: Rosuvastatin
7 Completed The Effect of Caffeine on Ischemic Preconditioning
Conditions: Caffeine;   Ischemic Preconditioning;   Ischemia-Reperfusion Injury
Interventions: Drug: caffeine;   Drug: Technetium-TC99m-labeled Annexin A5;   Procedure: ten minutes forearm ischemia;   Procedure: ischemic forearm exercise
8 Suspended Opioid Receptors Influence Ischemia-Reperfusion Injury
Condition: Ischemia-Reperfusion Injury
Interventions: Drug: morphine;   Drug: naloxone;   Drug: Technetium-TC99m-labeled Annexin A5;   Procedure: forearm ischemic exercise;   Procedure: ten minute forearm ischemia
9 Completed Does Atorvastatin Reduce Ischemia-Reperfusion Injury in Humans in-Vivo?
Conditions: Ischemia Reperfusion Injury;   Cardiovascular Disease
Intervention: Drug: atorvastatin
10 Recruiting Lestaurtinib With or Without Chemotherapy Agents in Samples From Young Patients With Leukemia
Conditions: Childhood Acute Lymphoblastic Leukemia;   Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies
Intervention: Other: laboratory biomarker analysis
11 Completed Does a Seven Day Treatment With Dipyridamole Induce Protection Against Ischemia-Reperfusion Injury?
Conditions: Ischemia-Reperfusion Injury;   Atherosclerosis
Intervention: Drug: dipyridamole
12 Completed Does Caffeine Reduce Dipyridamole-Induced Protection Against Ischemia-Reperfusion Injury?
Conditions: Cardiovascular Disease;   Ischemia-Reperfusion Injury
Interventions: Drug: Dipyridamole;   Drug: caffeine
13 Completed Does Caffeine Reduce Rosuvastatin-Induced Protection Against Ischemia-Reperfusion Injury?
Condition: Ischemia Reperfusion Injury
Intervention: Drug: Rosuvastatin
14 Recruiting DCE-MRI PET Bevacizumab Study in Rectal Cancer
Condition: Rectal Cancer Patients
Intervention: Drug: Bevacizumab 5 mg/kg
15 Active, not recruiting Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma
Conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   B-cell Adult Acute Lymphoblastic Leukemia;   B-cell Chronic Lymphocytic Leukemia;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Noncutaneous Extranodal Lymphoma;   Peripheral T-cell Lymphoma;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Refractory Hairy Cell Leukemia;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   T-cell Adult Acute Lymphoblastic Leukemia;   T-cell Large Granular Lymphocyte Leukemia;   Testicular Lymphoma;   Waldenström Macroglobulinemia
Interventions: Drug: Akt inhibitor MK2206;   Other: laboratory biomarker analysis
16 Recruiting Application of MACS and Time-lapse Technology in Good-prognosis Patients
Condition: MACS Technique Efficacy
Interventions: Other: MACS;   Other: NO MACS
17 Active, not recruiting Pilot Study of Raltegravir and Cisplatin in Squamous Cell Carcinoma of Head and Neck
Condition: Head and Neck Cancer
Intervention: Drug: raltegravir and cisplatin
18 Active, not recruiting Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 Given in a 3 Days on / 4 Days Off Schedule in Subjects With Advanced Malignancies
Condition: Neoplasms
Intervention: Drug: Roniciclib (BAY1000394)
19 Unknown  Evaluation of Endometrial Stromal Cell Apoptosis in Adenomyosis
Condition: Endometriosis
Intervention:
20 Unknown  Infusion of a Single Dose of Erythropoietin to Prevent Injury in an Ischemia Reperfusion Forearm Model
Conditions: Ischemia-Reperfusion Injury;   Myocardial Infarction
Interventions: Drug: Epoetin alpha;   Drug: NaCl

Previous Page Studies Shown (1-20) Next Page (21-24) Show next page of results
Indicates status has not been verified in more than two years